BOTYD Financials
This page shows BOTYD (BOTYD) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
BOTYD's sales growth is being financed, not earned, because new revenue still arrives below cost and cash stays thin.
By FY2025, revenue was roughly twice FY2022, yet gross margin fell from70.3% to-14.0% ; the problem moved below the gross-profit line, so added sales now deepen losses before overhead or interest. At the same time, operating cash burn matched free cash burn at-$313K because capex was$0 , showing cash use came from keeping the business running rather than expanding it.
The balance sheet is acting as a bridge, not a buffer: FY2025 financing brought in
Negative equity persisted and worsened across the last three reported balance sheets, so this is not just a one-year cash squeeze. Liabilities rose from
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of BOTYD's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
BOTYD has an operating margin of -215.9%, meaning the company retains $-216 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses.
BOTYD's current ratio of 0.01 is below the typical benchmark, resulting in a score of 0/100. This tight liquidity could limit financial flexibility if cash inflows slow.
While BOTYD generated -$313K in operating cash flow, capex of $0 consumed most of it, leaving -$313K in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
BOTYD passes 3 of 9 financial strength tests. 1 of 3 profitability signals pass, 2 of 3 leverage/liquidity signals pass.
For every $1 of reported earnings, BOTYD generates $0.55 in operating cash flow (-$313K OCF vs -$567K net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
BOTYD earns $-0.8 in operating income for every $1 of interest expense (-$450K vs $532K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
BOTYD generated $208K in revenue in fiscal year 2025.
BOTYD's EBITDA was -$449K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
BOTYD reported -$567K in net income in fiscal year 2025.
BOTYD earned $-1.14 per diluted share (EPS) in fiscal year 2025. This represents an increase of 74.6% from the prior year.
Cash & Balance Sheet
BOTYD generated -$313K in free cash flow in fiscal year 2025, representing cash available after capex.
BOTYD held $24K in cash against $0 in long-term debt as of fiscal year 2025.
BOTYD had 555,936 shares outstanding in fiscal year 2025. This represents a decrease of 100.0% from the prior year.
Margins & Returns
BOTYD's gross margin was -14.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs.
BOTYD's operating margin was -215.9% in fiscal year 2025, reflecting core business profitability.
BOTYD's net profit margin was -272.0% in fiscal year 2025, showing the share of revenue converted to profit.
Capital Allocation
BOTYD invested $0 in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 100.0% from the prior year.
BOTYD Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $49K-59.5% | $121K+255.6% | $34K+33.5% | $26K-7.0% | $27K | N/A | $24K-31.7% | $34K |
| Cost of Revenue | $41K-40.2% | $69K-52.9% | $145K+1049.6% | $13K+14.3% | $11K | N/A | $13K-46.4% | $23K |
| Gross Profit | $8K-84.4% | $53K+147.4% | -$111K-962.7% | $13K-21.4% | $16K | N/A | $11K-1.0% | $11K |
| R&D Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | $35K-1.6% | $36K+70.1% | $21K-67.8% | $65K+367.0% | $14K | N/A | $16K+22.9% | $13K |
| Operating Income | -$395K-925.9% | -$39K+83.3% | -$230K-115.8% | -$107K-43.3% | -$74K | N/A | -$158K-57.8% | -$100K |
| Interest Expense | $203K+89.2% | $107K-42.4% | $186K+43.0% | $130K+20.3% | $108K | N/A | $110K+15.5% | $95K |
| Income Tax | $0 | $0 | $0 | $0 | $0 | N/A | $0 | $0 |
| Net Income | $439K | N/A | N/A | N/A | N/A | N/A | -$770K-155.4% | $1.4M |
| EPS (Diluted) | $0.02 | N/A | $0.00 | $0.00-100.0% | $0.86 | N/A | $0.00 | $0.00 |
BOTYD Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $95K-10.1% | $106K-52.4% | $223K+43.2% | $156K+5572.1% | $3K-39.6% | $5K | N/A | N/A |
| Current Assets | $45K+11.2% | $40K-60.0% | $100K-35.0% | $154K+21536.5% | $713-67.5% | $2K-82.9% | $13K+22.8% | $10K |
| Cash & Equivalents | $31K+27.3% | $24K-69.8% | $80K-29.5% | $113K+15769.3% | $713-67.5% | $2K-82.9% | $13K+22.8% | $10K |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $2K-66.5% | $6K-30.9% | $8K | N/A | N/A | $0 | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $5.7M-11.8% | $6.4M+1.0% | $6.4M-17.4% | $7.7M+66.4% | $4.6M-21.8% | $5.9M | N/A | N/A |
| Current Liabilities | $5.7M-11.8% | $6.4M+1.5% | $6.3M-17.8% | $7.7M+66.4% | $4.6M-21.8% | $5.9M+4.4% | $5.7M+13.0% | $5.0M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$5.6M+11.9% | -$6.3M-3.0% | -$6.2M+18.7% | -$7.6M-63.1% | -$4.6M+21.8% | -$5.9M-4.5% | -$5.7M-13.0% | -$5.0M |
| Retained Earnings | -$11.3M+3.7% | -$11.7M-1.8% | -$11.5M+10.0% | -$12.8M-29.6% | -$9.9M+11.5% | -$11.2M-2.4% | -$10.9M-7.6% | -$10.1M |
BOTYD Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$85K-52.4% | -$56K+56.9% | -$129K-62.5% | -$80K-65.1% | -$48K | N/A | -$44K+50.7% | -$89K |
| Capital Expenditures | N/A | -$141K | N/A | N/A | N/A | $3K | N/A | N/A |
| Free Cash Flow | N/A | -$196K | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | N/A | $0 | N/A | N/A | N/A | -$3K | $0 | $0 |
| Financing Cash Flow | $92K | $0-100.0% | $237K+23.2% | $192K+310.9% | $47K+174.8% | $17K-63.4% | $47K-52.3% | $98K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
BOTYD Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 16.7%-26.8pp | 43.5%+369.7pp | -326.2%-376.7pp | 50.5%-9.3pp | 59.8% | N/A | 46.8%+14.5pp | 32.3% |
| Operating Margin | -803.1%-771.4pp | -31.7%+643.3pp | -675.1%-257.4pp | -417.7%-146.7pp | -270.9% | N/A | -671.8%-381.2pp | -290.6% |
| Net Margin | 893.0% | N/A | N/A | N/A | N/A | N/A | -3272.6%-7302.1pp | 4029.5% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | 460.2% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Current Ratio | 0.010.0 | 0.010.0 | 0.020.0 | 0.02+0.0 | 0.000.0 | 0.000.0 | 0.000.0 | 0.00 |
| Debt-to-Equity | -1.020.0 | -1.02+0.0 | -1.04-0.0 | -1.02-0.0 | -1.000.0 | -1.00 | N/A | N/A |
| FCF Margin | N/A | -161.7% | N/A | N/A | N/A | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$6.3M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.01), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Frequently Asked Questions
What is BOTYD's annual revenue?
BOTYD (BOTYD) reported $208K in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Is BOTYD profitable?
No, BOTYD (BOTYD) reported a net income of -$567K in fiscal year 2025, with a net profit margin of -272.0%.
What is BOTYD's EBITDA?
BOTYD (BOTYD) had EBITDA of -$449K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is BOTYD's gross margin?
BOTYD (BOTYD) had a gross margin of -14.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is BOTYD's operating margin?
BOTYD (BOTYD) had an operating margin of -215.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is BOTYD's net profit margin?
BOTYD (BOTYD) had a net profit margin of -272.0% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is BOTYD's free cash flow?
BOTYD (BOTYD) generated -$313K in free cash flow during fiscal year 2025. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is BOTYD's operating cash flow?
BOTYD (BOTYD) generated -$313K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are BOTYD's total assets?
BOTYD (BOTYD) had $106K in total assets as of fiscal year 2025, including both current and long-term assets.
What are BOTYD's capital expenditures?
BOTYD (BOTYD) invested $0 in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is BOTYD's current ratio?
BOTYD (BOTYD) had a current ratio of 0.01 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is BOTYD's debt-to-equity ratio?
BOTYD (BOTYD) had a debt-to-equity ratio of -1.02 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is BOTYD's return on assets (ROA)?
BOTYD (BOTYD) had a return on assets of -534.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is BOTYD's cash runway?
Based on fiscal year 2025 data, BOTYD (BOTYD) had $24K in cash against an annual operating cash burn of $313K. This gives an estimated cash runway of approximately 1 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is BOTYD's debt-to-equity ratio negative or unusual?
BOTYD (BOTYD) has negative shareholder equity of -$6.3M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is BOTYD's Piotroski F-Score?
BOTYD (BOTYD) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are BOTYD's earnings high quality?
BOTYD (BOTYD) has an earnings quality ratio of 0.55x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can BOTYD cover its interest payments?
BOTYD (BOTYD) has an interest coverage ratio of -0.8x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is BOTYD?
BOTYD (BOTYD) scores 0 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.